Synergistic interactions between SCFA-producing bacteria and anti-inflammatory drugs may be a valuable treatment option for people with IBD, while strategies that modulate IL-10 and NF-κB may also have therapeutic potential [8,9]. This evidence concerns the gene NFKB1 and inflammatory bowel disease.